Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Iodine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 20Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    IBSA Introduces Two New Dietary Supplements Into the U.S. Market
    IBSA Introduces Two New Dietary Supplements Into the U.S. Market

    07 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240506085709/en

    BUSINESSWIRE
    07 May 2024
    Share Share
    Enforcement Report - Week of November 8, 2023
    Enforcement Report - Week of November 8, 2023

    08 Nov 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-8-2023-82126.pdf

    FDA
    08 Nov 2023
    Share Share
    Attralus Receives FDA and EMA Orphan Designation for AT-01
    Attralus Receives FDA and EMA Orphan Designation for AT-01

    19 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/12/19/2576139/0/en/Attralus-Receives-FDA-and-EMA-Orphan-Designation-for-AT-01-Iodine-I-124-Evuzamitide-an-Investigational-Diagnostic-for-the-Management-of-AL-and-ATTR-Amyloidosis.html

    GLOBENEWSWIRE
    19 Dec 2022
    Share Share
    Attralus Announces New Clinical Data in ATTR CM and AL With AT-01
    Attralus Announces New Clinical Data in ATTR CM and AL With AT-01

    12 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/12/2513836/0/en/Attralus-Announces-New-Clinical-Data-in-ATTR-CM-and-AL-With-AT-01-Iodine-I-124-Evuzamitide-a-Novel-Amyloid-Specific-Imaging-Agent.html

    GLOBENEWSWIRE
    12 Sep 2022
    Share Share
    Novo Integrated Sciences Granted NPN for IoNovo Iodine Branded Product
    Novo Integrated Sciences Granted NPN for IoNovo Iodine Branded Product

    23 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211223005093/en

    BUSINESSWIRE
    23 Dec 2021
    Share Share
    Novo Integrated Sciences Granted NPN for IoNovo Iodine Branded Product
    Novo Integrated Sciences Granted NPN for IoNovo Iodine Branded Product

    23 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211223005093/en

    BUSINESSWIRE
    23 Dec 2021
    Share Share